Eli Lilly Taps Insilico in $2.75 Billion AI Drug Deal
The agreement gives Eli Lilly rights to AI-developed drug candidates as big pharma hunts faster and cheaper ways to build pipelines.
Topics
News
- UP Pulls Plug on Puch AI Deal Over Financial Gaps
- Blackstone-Backed EPL to Merge With Indorama Unit in $2 Billion Packaging Deal
- Eli Lilly Taps Insilico in $2.75 Billion AI Drug Deal
- Apple Hires Former Google Executive as it Retools Siri
- Allianz Jio Re Appoints Sonia Rawal CEO as India Operations Begin
- English Wikipedia Restricts Use of Generative AI in Article Writing
US pharmaceutical company Eli Lilly has signed a deal worth up to $2.75 billion to commercialize drugs developed by Hong Kong-based Insilico Medicine in one of the bigger wagers on artificial intelligence in pharmaceutical research.
Insilico will receive $115 million upfront, with the rest tied to development, regulatory and commercial milestones, plus tiered royalties on future sales.
The agreement gives Lilly exclusive worldwide rights to develop, make and sell selected oral drugs now in preclinical development using Insilico’s AI platform.
Like many biotech partnerships, most of the headline figure depends on whether the programs survive testing and eventually reach the market.
Insilico says it has developed at least 28 drugs using generative AI tools, with nearly half already in clinical stages.
The company’s pitch is speed: AI models that can design and optimize molecules faster than traditional lab-driven discovery. Whether that speed translates into approved therapies at scale is still an open question.
The deal adds another route into AI-powered drug discovery for Lilly as large drugmakers look for faster and cheaper ways to build pipelines.
“This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates,” said Andrew Adams, group vice president of Molecule Discovery at Lilly, in a statement, describing Insilico’s technology as a “complement” to its existing clinical capabilities.
Pointing to the complementary nature of the partnership, Insilico Medicine Founder and CEO Alex Zhavoronkov pointed to Lilly’s deeper capabilities in areas such as integrating biology, chemistry, and automation.
“Lilly is better than us in some areas of AI,” Zhavoronkov told CNBC, adding that Insilico will join Lilly’s Gateway Labs ecosystem as part of the collaboration.
The two companies are not starting from scratch. They have been working together since a 2023 AI software licensing agreement. The new deal expands that relationship into full-fledged drug development and commercialization.
The timing also intersects with Lilly’s broader global strategy. Eli Lilly CEO David A. Ricks was recently in Beijing for a high-level forum, shortly after the company announced plans to invest $3 billion in China over the next decade. Despite that push, China currently contributes less than 3% of Lilly’s revenue.
Insilico’s own operating model reflects the fragmented geography of AI drug development. While its AI systems are built outside China, in places like Canada and the Middle East, early-stage preclinical work is conducted in China.
